[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352440-105":59,"doc-detail-352440-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","metabolic-reprogramming-driven-resistance-to-multi-kinase-inhibitors-in-hepatocellular-carcinoma-molecular-mechanismsand-therapeutic-opportunities","Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanismsand therapeutic opportunities","","Hepatocellular carcinoma (HCC), the most common primary liver cancer, is often diagnosed at advanced stages, limiting curative options. Multi-kinase inhibitors (MKIs), including sorafenib and lenvatinib, are first-line therapies for unresectable HCC, yet drug resistance substantially reduces efficacy and leaves few strategies to restore sensitivity. This review analyzes how metabolic reprogramming—especially glycolysis, lipid metabolism, and amino acid metabolism—promotes MKI resistance, identifies molecular regulators as targets, and summarizes preclinical and clinical combination opportunities. It also examines metabolic reprogramming’s impact on the tumor immune microenvironment (TIME).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metabolic-reprogramming-driven-resistance-to-multi-kinase-inhibitors-in-hepatocellular-carcinoma-molecular-mechanismsand-therapeutic-opportunities/352440/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metabolic-reprogramming-driven-resistance-to-multi-kinase-inhibitors-in-hepatocellular-carcinoma-molecular-mechanismsand-therapeutic-opportunities/352440.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is drug resistance a major limitation of multi-kinase inhibitors in hepatocellular carcinoma?","Question",{"text":113,"@type":114},"MKIs such as sorafenib and lenvatinib face widespread development of drug resistance, which markedly diminishes clinical efficacy. Current treatments do not provide effective strategies to enhance MKI sensitivity.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which metabolic processes does the review highlight as drivers of MKI resistance in HCC?",{"text":118,"@type":114},"The review focuses on glycolysis, lipid metabolism, and amino acid metabolism as key components of metabolic reprogramming that promote MKI resistance.",{"name":120,"@type":111,"acceptedAnswer":121},"What therapeutic strategies are discussed to improve MKI outcomes?",{"text":122,"@type":114},"The review synthesizes evidence for therapeutic agents that synergize with MKIs by modulating metabolic pathways. It also discusses how metabolic reprogramming regulates the tumor immune microenvironment (TIME) to enable innovative treatment strategies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352440,1790182605,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Li et al. Molecular Cancer (2026) 25:37 [https://doi.org/10.1186/s12943-026-02578-w](https://doi.org/10.1186/s12943-026-02578-w)  \nMolecular Cancer  \nREVIEW Open Access  \nMetabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanismsand therapeutic opportunities  \nJunxin Li1*, Yu Huang1, Jiawei Li2, Min Shi1, Yi Xiao1, Fei Du3 and Gongli Hu 1*  \nAbstract  \nHepatocellular carcinoma (HCC), the most common form of primary liver cancer, is frequently diagnosed at advanced stages, limiting curative options. Multi-kinase inhibitors (MKIs), such as sorafenib and lenvatinib, serve as first-line therapies for unresectable HCC. However, the widespread development of drug resistance significantly diminishes the clinical efficacy of MKIs, and current treatments lack effective strategies to enhance MKI sensitivity. Metabolic reprogramming, a hallmark of cancer cells that facilitates unchecked growth and metastasis, has emerged as a critical mechanism driving MKI resistance in HCC. This review comprehensively examines the roles of glycolysis, lipid metabolism, and amino acid metabolism in promoting MKI resistance, with a focus on key molecular regulators that could serve as potential targets to reverse resistance. Additionally, this review synthesizes preclinical and clinical evidence of therapeutic agents that synergize with MKIs by modulating metabolic pathways, and discusses the regulatory role of metabolic reprogramming in the tumor immune microenvironment (TIME) of HCC, offering innovative strategies to improve treatment outcomes for patients with HCC. These findings highlight metabolic reprogramming as a crucial target for developing novel interventions aimed at overcoming MKI resistance in clinical practice.  \nKeywords HCC, Drug resistance, Metabolic reprogramming, Glycolysis, Lipid metabolism, Amino acid metabolism, TME, MKIs, Sorafenib, Lenvatinib  \n*Correspondence: Junxin Li  \nljx1 [110718@163.com](110718@163.com)  \nGongli Hu  \n[807080229@qq.com](807080229@qq.com)  \n1Department of Pharmacy, Zigong Fourth People’s Hospital, Zigong 643000, China  \n2Department of Oncology, Zigong Fourth People’s Hospital, Zigong 643000, China  \n3Department of Pharmacy, The Fourth Affiliated Hospital of Southwest Medical University, Meishan 620000, China  \nIntroduction  \nNutrient metabolism is a vital physiological process in cells. In contrast to normal cells, cancer cells exhibit uncontrolled proliferation, migration, and invasion. To meet their bioenergetic and biosynthetic demands in nutrient-deprived microenvironments, cancer cells undergo metabolic reprogramming, a process that sustains their growth and survival [1]. Metabolic reprogramming includes alterations such as the Warburg effect, lipid metabolism, and amino acid metabolism [2, 3]. These changes are marked by enhanced aerobic glycolysis and increased biosynthesis of macromolecules, such as  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/","cbCaihdNBtX0gaC5","https://ap.wps.com/l/cbCaihdNBtX0gaC5","pdf",3239438,31,"English","# Abstract\n## Introduction","[{\"question\":\"Why is drug resistance a major limitation of multi-kinase inhibitors in hepatocellular carcinoma?\",\"answer\":\"MKIs such as sorafenib and lenvatinib face widespread development of drug resistance, which markedly diminishes clinical efficacy. Current treatments do not provide effective strategies to enhance MKI sensitivity.\"},{\"question\":\"Which metabolic processes does the review highlight as drivers of MKI resistance in HCC?\",\"answer\":\"The review focuses on glycolysis, lipid metabolism, and amino acid metabolism as key components of metabolic reprogramming that promote MKI resistance.\"},{\"question\":\"What therapeutic strategies are discussed to improve MKI outcomes?\",\"answer\":\"The review synthesizes evidence for therapeutic agents that synergize with MKIs by modulating metabolic pathways. It also discusses how metabolic reprogramming regulates the tumor immune microenvironment (TIME) to enable innovative treatment strategies.\"}]","Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanismsand therapeutic opportunities | PDF",1790099642,78,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/829725968aba6afe206fe70f9f482d80.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/793a787702ee9d6182d675080b6926ac.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea143979a339b7082e3ecb913db9efbb.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a891da694e9fac5b0163a482b379eef4.webp",980,1306]